Company news

Sarepta Therapeutics, Inc. news in 2024

Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

December 17, 2024

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

November 25, 2024

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

November 5, 2024

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

October 22, 2024

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

September 25, 2024

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

September 15, 2024

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

September 4, 2024

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 29, 2024

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

August 6, 2024

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

July 28, 2024

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

June 19, 2024

Sarepta Therapeutics Set to Join S&P MidCap 400

May 28, 2024

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

May 2, 2024

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

April 30, 2024

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

April 23, 2024

Sarepta Therapeutics to Present at Upcoming Investor Conferences

March 3, 2024

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

February 28, 2024

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

February 27, 2024

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

February 20, 2024

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

February 15, 2024

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

January 28, 2024

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

January 15, 2024

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

January 7, 2024

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Calls in 2024